Smith, Amanda R.
Weinstock, Matthew T.
Siglin, Amanda E.
Whitby, Frank G.
Francis, J. Nicholas
Hill, Christopher P.
Eckert, Debra M.
Root, Michael J.
Kay, Michael S. http://orcid.org/0000-0003-3186-9684
Funding for this research was provided by:
National Institutes of Health (AI076168, AI150490, AI150464)
Article History
Received: 27 August 2019
Accepted: 3 October 2019
First Online: 22 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors declare the following competing financial interest(s): MSK and DME are consultants and equity holders in Navigen, Inc., which is commercializing <scp>d-</scp>peptide inhibitors of HIV entry.